SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 for CB1 activation of 19nM, and 7x selectivity for CB1 over CB2. It was discovered during research into the related compound SDB-001 which had been sold illicitly as "2NE1".
^Banister, S. D.; Wilkinson, S. M.; Longworth, M.; Stuart, J.; Apetz, N.; English, K.; Brooker, L.; Goebel, C.; Hibbs, D. E.; Glass, M.; Connor, M.; McGregor, I. S.; Kassiou, M. (2013). "The synthesis and pharmacological evaluation of adamantane-derived indoles: Novel cannabimimetic drugs of abuse". ACS Chemical Neuroscience4 (7): 130403084729007. doi:10.1021/cn400035r.edit